Specific Diagnostics

About

Specific Diagnostics, based in San Jose, California, was founded in 2010 and specialized in in vitro diagnostic systems. The company developed innovative technologies for detecting and assessing antibiotic susceptibility of microorganisms directly from blood cultures. Their focus on rapid antimicrobial susceptibility testing (AST) aimed to address sepsis and antimicrobial resistance, providing results in an average of 5 hours, significantly faster than traditional methods. One of their key products, the Reveal Rapid AST System, utilizes sensor arrays to detect microbial growth and quantify antibiotic efficacy. This system streamlines lab workflows and enhances patient outcomes by delivering timely results. Specific Diagnostics also held a patent for detecting drug resistance in microorganisms, which supports their applications in infectious diseases and intensive care. The company was acquired by bioMérieux in May 2022, enhancing bioMérieux's capabilities in clinical microbiology and antimicrobial resistance. Specific Diagnostics had around 100 employees and raised over $39 million prior to its acquisition, with notable investors including the National Institute of Allergy and Infectious Diseases and the U.S. Army.